Skip to main content
. Author manuscript; available in PMC: 2010 Nov 8.
Published in final edited form as: Neurosci Lett. 2006 Mar 22;401(1-2):130–135. doi: 10.1016/j.neulet.2006.03.001

Fig. 1.

Fig. 1

Parkin gene delivery with AAV vector. (A) Parkin immunoblot of soluble fraction from human embryonic kidney 293 cells treated with the human parkin AAV 4 days earlier. The ~50 kDa band was not observed in untreated or control GFP AAV treated cells under these blotting conditions. (B) Parkin immunoblot of dissected rat substantia nigra that were injected with control GFP or human parkin AAV vectors 12 weeks earlier at a dose of 2 × 1010 particles (3 rats/group, 50 μg protein loaded in each lane) showing parkin transgene product expression in the parkin vector group. Size markers in kDa in first lane. (C) Substantia nigra section from a parkin AAV-injected rat as in B processed for parkin immunostaining. Parkin staining in uninjected or GFP AAV injected tissues was blank under these conditions. Bar = 125 μm.